Aptose signs crada with nci to develop tuspetinib for aml and mds in newly launched myelomatch precision medicine trials

Aptose's aml drug tuspetinib selected for nci's prestigious clinical research program for ability to target broad spectrum of aml and mds populations

NCI Ratings Summary

NCI Quant Ranking